Search company, investor...

LigoCyte Pharmaceuticals

ligocyte.com

Founded Year

1998

Stage

Acquired | Acquired

Total Raised

$57.22M

Valuation

$0000 

About LigoCyte Pharmaceuticals

Ligocyte focuses on cellular immunology and new approaches to fight dangerous pathogens. The company's lead programs include vaccines against norovirus, anthrax and influenza. The company was founded in 1998 and is based in Bozeman, Montana.

Headquarters Location

2155 Analysis Drive

Bozeman, Montana, 59718,

United States

406-585-2733

Missing: LigoCyte Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LigoCyte Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LigoCyte Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LigoCyte Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

LigoCyte Pharmaceuticals Patents

LigoCyte Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/15/2013

7/3/2018

Vaccines, Dosage forms, Virus families, Animal virology, Molecular biology

Grant

Application Date

3/15/2013

Grant Date

7/3/2018

Title

Related Topics

Vaccines, Dosage forms, Virus families, Animal virology, Molecular biology

Status

Grant

Latest LigoCyte Pharmaceuticals News

LigoCyte Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 1, 2016

LigoCyte Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 11:47 EST 1 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » LigoCyte Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' LigoCyte Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by LigoCyte Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on LigoCyte Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by LigoCyte Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for LigoCyte Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about LigoCyte Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

LigoCyte Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was LigoCyte Pharmaceuticals founded?

    LigoCyte Pharmaceuticals was founded in 1998.

  • Where is LigoCyte Pharmaceuticals's headquarters?

    LigoCyte Pharmaceuticals's headquarters is located at 2155 Analysis Drive, Bozeman.

  • What is LigoCyte Pharmaceuticals's latest funding round?

    LigoCyte Pharmaceuticals's latest funding round is Acquired.

  • How much did LigoCyte Pharmaceuticals raise?

    LigoCyte Pharmaceuticals raised a total of $57.22M.

  • Who are the investors of LigoCyte Pharmaceuticals?

    Investors of LigoCyte Pharmaceuticals include Takeda Pharmaceutical, Novartis Venture Funds, Forward Ventures, F-Prime Capital, Frontier Angel Fund and 10 more.

  • Who are LigoCyte Pharmaceuticals's competitors?

    Competitors of LigoCyte Pharmaceuticals include BlueWillow Biologics, ISA Pharmaceuticals, CVRx, Bellicum Pharmaceuticals, Immune Design and 12 more.

Compare LigoCyte Pharmaceuticals to Competitors

S
Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology.  The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University.  Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com

I
ISA Pharmaceuticals

ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

V
Vivaldi Biosciences

Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the Mount Sinai School of Medicine, Vivaldi's program represents a approach to flu vaccine development and production and a major advance over flu vaccines available today.

C
Creatogen

Creatogen, a spin-off from the Max Planck Institute for Infection Biology in Berlin, develops bacterial carriers for oral delivery to treat and prevent acute and chronic diseases caused by an imbalance of the immune system.

I
ImmBio

ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.